| Ernest Marshall Graham, MD | |
|
601 N Caroline St, Baltimore, MD 21287-0006 | |
| (410) 955-6700 | |
| Not Available |
| Full Name | Ernest Marshall Graham |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 37 Years |
| Location | 601 N Caroline St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144272907 | NPI | - | NPPES |
| 300109100 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D54187 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Entity Name | Sinai Hospital Of Baltimore, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043235666 PECOS PAC ID: 0941112346 Enrollment ID: O20031104000353 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Entity Name | Baltimore Medical System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700882503 PECOS PAC ID: 5395653455 Enrollment ID: O20031121000651 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Entity Name | Union Hospital Of Cecil County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124067848 PECOS PAC ID: 6901719822 Enrollment ID: O20040121001109 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Entity Name | University Of Maryland St Joseph Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770836785 PECOS PAC ID: 4880846179 Enrollment ID: O20121213000234 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ernest Marshall Graham, MD Po Box 64313, Baltimore, MD 21264-4313 Ph: () - | Ernest Marshall Graham, MD 601 N Caroline St, Baltimore, MD 21287-0006 Ph: (410) 955-6700 |
News Archive
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
The U.S. Food and Drug Administration (FDA) has cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as individuals in other trauma settings and emergency situations.
Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.
› Verified 9 days ago
Miss Elizabeth Unique Morris, MSN, WHNP-BC Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 330 N Howard St, Baltimore, MD 21201 Phone: 410-576-1414 | |
Christine E. O Connor, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 227 Saint Paul St, 6th Floor, Baltimore, MD 21202 Phone: 410-332-9002 Fax: 410-783-5880 | |
Fateh Hraky Sr., Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3001 S Hanover St, Suite 301, Baltimore, MD 21225 Phone: 410-350-0800 | |
Joyce A Bonsu, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3449 Wilkens Ave Ste 305, Baltimore, MD 21229 Phone: 410-644-2582 Fax: 410-644-6232 | |
Fouad M Abbas, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2411 W Belvedere Ave, Suite 206, Baltimore, MD 21215 Phone: 410-601-9030 | |
Dr. Ginny M Merryman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6569 N Charles St, Suite 501, Baltimore, MD 21204 Phone: 410-938-8960 Fax: 410-583-9770 | |
Dr. Golsa Mirmiran Yazdy, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave Bldg A1, Baltimore, MD 21224 Phone: 410-550-0337 Fax: 410-550-0196 |